SG
BMY icon

StoneX Group’s Bristol-Myers Squibb BMY Stock Holding History

StoneX Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$548K Buy
9,503
+3,588
+61% +$206K 0.02% 524
2026
Q1 		$358K Sell
5,915
-4,548
-43% -$265K 0.02% 512
2025
Q4 		$565K Buy
10,463
+683
+7% +$32.9K 0.02% 499
2025
Q3 		$441K Sell
9,780
-2,358
-19% -$110K 0.02% 579
2025
Q2 		$562K Sell
12,138
-4,377
-27% -$215K 0.03% 461
2025
Q1 		$1.01M Buy
16,515
+1,646
+11% +$95.9K 0.06% 287
2024
Q4 		$841K Sell
14,869
-1,397
-9% -$78.1K 0.05% 324
2024
Q3 		$842K Buy
16,266
+1,593
+11% +$74.7K 0.06% 250
2024
Q2 		$609K Buy
14,673
+298
+2% +$13.3K 0.05% 293
2024
Q1 		$780K Buy
14,375
+583
+4% +$29.7K 0.07% 240
2023
Q4 		$708K Sell
13,792
-12,044
-47% -$632K 0.07% 242
2023
Q3 		$1.5M Buy
25,836
+1,523
+6% +$93.3K 0.16% 112
2023
Q2 		$1.55M Sell
24,313
-1,309
-5% -$87.8K 0.16% 119
2023
Q1 		$1.78M Buy
25,622
+2,507
+11% +$177K 0.19% 96
2022
Q4 		$1.66M Buy
23,115
+925
+4% +$69.7K 0.2% 98
2022
Q3 		$1.58M Sell
22,190
-3,009
-12% -$218K 0.22% 95
2022
Q2 		$1.95M Buy
25,199
+12,072
+92% +$919K 0.24% 84
2022
Q1 		$965K Sell
13,127
-3,307
-20% -$222K 0.08% 225
2021
Q4 		$1.02M Sell
16,434
-3,092
-16% -$181K 0.12% 165
2021
Q3 		$1.17M Buy
19,526
+1,052
+6% +$69.3K 0.17% 136
2021
Q2 		$1.23M Buy
18,474
+1,090
+6% +$71.1K 0.18% 118
2021
Q1 		$1.11M Buy
17,384
+562
+3% +$35K 0.2% 98
2020
Q4 		$1.05M Buy
16,822
+114
+0.7% +$7.01K 0.23% 87
2020
Q3 		$1.01M Buy
16,708
+779
+5% +$46.9K 0.32% 68
2020
Q2 		$937K Sell
15,929
-32
-0.2% -$1.91K 0.36% 69
2020
Q1 		$890K Sell
15,961
-7,127
-31% -$436K 0.47% 56
2019
Q4 		$1.48M Buy
+23,088
New +$1.32M 0.6% 43
2017
Q3 		– Sell
-6,928
Closed -$386K – 195
2017
Q2 		$386K Buy
+6,928
New +$377K 0.12% 233

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

StoneX Group's BMY Position: Q2 2026 in Review

StoneX Group increased its Bristol-Myers Squibb (BMY) stake by 61% in Q2 2026, buying an estimated $206K and bringing the position to 9,503 shares worth $548K. The position accounts for 0.02% of the portfolio, ranked #524.

StoneX Group first reported a position in BMY in Q2 2017 and has held it in 28 quarters since. The position peaked at $1.95M in Q2 2022. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • StoneX Group held 9,503 shares of Bristol-Myers Squibb worth $548K as of Q2 2026.
  • StoneX Group bought 3,588 Bristol-Myers Squibb shares in Q2 2026, an estimated $206K.
  • Bristol-Myers Squibb made up 0.02% of StoneX Group's portfolio in Q2 2026, its #524 holding.
  • StoneX Group first reported a position in Bristol-Myers Squibb in Q2 2017 and has held it in 28 quarters since.
  • StoneX Group's Bristol-Myers Squibb position peaked at $1.95M in Q2 2022.
  • 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.